1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Ocular Hypertension Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Ocular Hypertension Market, by Drug Type
8.1.1. Prostaglandin Analogs
8.1.1.1. Market Revenue and Forecast
8.1.2. Beta-Blockers
8.1.2.1. Market Revenue and Forecast
8.1.3. Alpha Agonists
8.1.3.1. Market Revenue and Forecast
8.1.4. Carbonic Anhydrase Inhibitors
8.1.4.1. Market Revenue and Forecast
8.1.5. Brinzolamide
8.1.5.1. Market Revenue and Forecast
9.1. Ocular Hypertension Market, by Treatment Type
9.1.1. Medical Treatment
9.1.1.1. Market Revenue and Forecast
9.1.2. Surgical Treatment
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Ocular Hypertension Market, by Route of Administration
10.1.1. Topical
10.1.1.1. Market Revenue and Forecast
10.1.2. Oral
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Ocular Hypertension Market, by Distribution Channel
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Type
12.1.2. Market Revenue and Forecast, by Treatment Type
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Type
12.1.5.2. Market Revenue and Forecast, by Treatment Type
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Type
12.1.6.2. Market Revenue and Forecast, by Treatment Type
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Type
12.2.2. Market Revenue and Forecast, by Treatment Type
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Type
12.2.5.2. Market Revenue and Forecast, by Treatment Type
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Type
12.2.6.2. Market Revenue and Forecast, by Treatment Type
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Type
12.2.7.2. Market Revenue and Forecast, by Treatment Type
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Type
12.2.8.2. Market Revenue and Forecast, by Treatment Type
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Type
12.3.2. Market Revenue and Forecast, by Treatment Type
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Type
12.3.5.2. Market Revenue and Forecast, by Treatment Type
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Type
12.3.6.2. Market Revenue and Forecast, by Treatment Type
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Type
12.3.7.2. Market Revenue and Forecast, by Treatment Type
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Type
12.3.8.2. Market Revenue and Forecast, by Treatment Type
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Type
12.4.2. Market Revenue and Forecast, by Treatment Type
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Type
12.4.5.2. Market Revenue and Forecast, by Treatment Type
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Type
12.4.6.2. Market Revenue and Forecast, by Treatment Type
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Type
12.4.7.2. Market Revenue and Forecast, by Treatment Type
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Type
12.4.8.2. Market Revenue and Forecast, by Treatment Type
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Type
12.5.2. Market Revenue and Forecast, by Treatment Type
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Type
12.5.5.2. Market Revenue and Forecast, by Treatment Type
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Type
12.5.6.2. Market Revenue and Forecast, by Treatment Type
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Allergan, Inc. (AbbVie Inc.)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Novartis AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Johnson & Johnson
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Santen Pharmaceutical Co., Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck & Co., Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Aerie Pharmaceuticals, Inc
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bausch Health Companies Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Teva Pharmaceutical Industries Ltd
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
